

TIW

Dykema Docket No. 065379-0053

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Joerg ROSENBERG et al.	)	Examiner:	Jennif	er Y. CHO
Serial No.:	10/539,505	)	Group Art Uni	t:	1621
Filed: Decem	ber 16, 2003	)	Confirmation	No.:	4705
A Physio	tion Comprising Fenofibric Acid, logically Acceptable Salt or e Thereof	) ) )			

#### INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

Attached Form PTO/SB/08A lists references which may be considered to be material to the above-identified application by the Patent Examiner. Entry into the record is respectfully requested. You are hereby authorized to charge the fee of \$180.00 and if any additional fees are incurred as a result of the filing of this paper, to deposit account number: 04-2223.

Respectfully submitted

Lisa V. Mueller, Reg. No. 38,978

Dykema Gossett PLLC 10 South Wacker Drive, Suite 2300 Chicago, Illinois 60606 USA (312)-876-1700 (312)-876-2302 (Facsimile)

#### **CERTIFICATE OF MAILING**

I hereby certify that this paper is being deposited with the United States Postal Service with sufficient postage at First Class Mail in an envelope addressed to: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on August 23, 2007.

08/28/2007 RFENABUL 00000018 042223 10539505

AUG 2 7 2007

PTO/SB/08a (08-03)

Approved for use through 07/31/2006, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

#### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

_	Application Number	10539505
	Filing Date	2003-12-16
	First Named Inventor	Rosenberg, et al.
	Art Unit	1621
	Examiner Name .	Jennifer Y. Cho
	Attorney Docket Number	065379-0053

	U.S.PATENTS							
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	5179097		1993-01-12	Angres, Isaac			
	2	4160020		1979-07-03	Alza Corporation			
	3	4340585	·	1982-07-20	Alfa Farmaceutici, S.p.A.			
	4	4233298		1980-11-11	Orchimed S.A.			
	5	4800079		1989-01-24	Boyer, Jean-Francols			
	6	6284803		2001-09-04	BASF Aktiengesellschaft			
	7 :	4859703	_	1989-08-22	Warner-Lambert Company			
	8	4372954	·	1983-02-08	Moreau, Pierre et al.			

Application Number	10539505			
Filing Date	2003-12-16			
First Named Inventor	Rosenberg, et al.			
Art Unit	1621	٠,		
Examiner Name	Jennifer Y. Cho			
Attorney Docket Number	065379-0053			

r			<del>,</del>	· · · · · · · · · · · · · · · · · · ·	Υ	
	9 .	4235896		1980-11-25	Orchimed S.A.	
	10	4179515		1979-12-18	Orchimed S.A.	
	11	4072705		1978-02-07	Orchimed S.A.	
	12	4058552		1977-11-15	Orchimed S.A.	
	13	3914286		1975-10-21	Orchimed S.A.	
	14	3907792		1975-09-23	Mieville	
	15	4895726	٠	1990-01-23	Fournier innovation et Synergie	
	16	6074670		2000-08-13	Laboratoires Fournier, S.A.	
	17	6277405	,	2001-08-21	Laboratoires Fournier, S.A.	
	18	5286497		1994-02-15	Carderm Capital L.P.	
	19	5737320		1998-04-07	Excel Switching Corporation	

Application Number	10539505		
Filing Date	2003-12-16		
First Named Inventor	Rosenberg, et al.		
Art Unit	1621		
Examiner Name	Jennifer Y. Cho		
Attorney Docket Number	065379-0053		

 		····			
20	4088864	·	1978-05-09	Alza Corporation	
21 <sub>.</sub>	4200098		1980-04-29	Alza Corporation	
22	5573776		1996-11-12	Alza Corporation	
23	3173876		1965-03-16	Zobrist	
24	3276586		1966-10-04	Rosaen Filter Company	
25	3541005		1970-11-17	Amicon Corporation	
26	3541008		1970-11-17	Amicon Corporation	
27	3546142		1970-12-08	Amicon Corporation	
28	3133132		1964-03-12	The Regents of the University of California	
29	3845770		1974-11-05	Alza Corporation	
30	3916899		1974-11-04	Alza Corporation	

Application Number	10539505		
Filing Date	2003-12-16		
First Named Inventor	Rosenberg, et al.		
Art Unit	1621		
Examiner Name	Jennifer Y. Cho		
Attorney Docket Number	065379-0053		

	31	2799241		1957-07-16	Wisconsin Alumni Research Foundation	
	32	4803081		1989-02-07	Aktiebolaget Hassle	
	33	4574080		1986-03-04	A/S Alfred Benzon	
	34	6514531		2003-02-04	Sanofl-Synthelabo	
If you wis	h to ac	dd additional U.S. Paten			lease click the Add button.	
			U.S.P	ATENT APPLI	CATION PUBLICATIONS	*.
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20010006662		2001-07-05	Krill, Steven et al.	
,	2	20030077297	A1 ·	2003-04-24	Chen, Feng-Jing, et al.	
	3	20050008704	. :	2005-01-13	Ray, et al.	
•	4	20050101561		2005-05-12	Tunac, et al.	
	5	20050148594		2005-07-07	Cink, et al.	

Application Number	10539505
Filing Date	2003-12-16
First Named Inventor	Rosenberg, et al.
Art Unit	1621
Examiner Name	Jennifer Y. Cho
Attorney Docket Number	0653 <b>7</b> 9 <b>-</b> 0053

<u> </u>	·		<u></u>						
	6	20040013697		2004-0	1-22	Berndi, et al.		·	
,,,,	7	20050008704		2005-01	1-13	Ray, et al.			
	8	20030086976		2003-08	5-08	Hayes, et al.			
If you wis	h to a	dd additional U.S. Publ					please click the Add butte	on.	<del></del>
			<del></del>	FOREI	GN PAT	TENT DOCUM	IENTS	·	<del>,</del>
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code4	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	т5
	1	474039	ES			1979-05-01			
:	2	2494112	FR			1982-05-21	Laruelle, Claude		
	ż	0173293	EP		B1	1991-10-30	Merrell Dow Pharmaceuticals inc.	:	
	4	01/03693	wo		A1	2001-01-18	Laboratoires Des Produits Ethiques Ethypharm		
	5	02/11699	wo		A1	2002-02-14	IMPAX Laboratories, Inc.		. 🗆
	.6	2004/054568	wo .		A1	2001-07-01	Abbott GMBH & Co. Kg		

Y	<del></del>
Application Number	10539505
Filing Date	2003-12-16
First Named Inventor	Rosenberg, et al.
Art Unit	1621
Examiner Name	Jennifer Y. Cho
Attorney Docket Number	065379-0053

	7	1415295	GB		1975-11-26	Mieville, Andre		
	8	1570488	GB		1980-07-02	Brisson, Henri, et al.		
	9	98/05331	wo		1998-02-12	Ligand Pharmaceuticals Incorporated		
	10	2004028506	wo		2004-04-08			
If you wis	h to a	dd additional Foreign P	atent Document	citation	information pl	ease click the Add butto	n	<del></del>
			NON-PATEN	NT LITE	RATURE DO	CUMENTS		
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.				Т5		
	1	International Conference on Harmonisation; Guideline for the Photostability Testig of New Drug substances and Products; Availability, Federal Register, Part II, Department of Health and Human Services, May 16, 1997, 27115-22, Vol. 62, No. 95						
	2	Photochemical Reactions, Solid-State Chemistry of Drugs, 2nd edition, 1999, 391-416, SSCI, Inc., West Lafayette, Indiana						
	3	Optical Microscopy, USP, 2002, 2040-2042, Vol. 25, Chapter 776, published by the United States Pharmacopeia						
·	4	ALBINI, A., et al. Photochemistry of Drugs: An Overview and Practical Problems, Drugs Photochemisty and Photostability, 1998, 1-73, The Royal Society of Chemisty						
·	5	TONNESEN, H. et al., Photoreactivity of biologically active compounds. XIII. Photostability of mefloquine hydrochloride in the solid state., Drug Stability, 249-253, Vol. 1, No. 4						

Application Number	10539505
Filing Date	2003-12-16
First Named Inventor	Rosenberg, et al.
Art Unit	1621
Examiner Name	Jennifer Y. Cho
Attorney Docket Number	065379-0053

	6	PRICE, S.L. et al., The computational prediction of pharmaceutical crystal sturcures and polymporphism, Advanced Drug Delivery Reviews, 2004, 301-319, Vol. 56	
	7	NORD, K. et al., Photoreactivity of biologically active compounds. XII. Photostability of polymorphic modicfications of chloroquine diphosphate, Drug Stability 1997, 243-248, Vol. 1, No. 4	
	8	MATSUDA, Y. et al., Pharmaceutical evaluation of carbamazepine modifications: comparative study for photostability of carbamazepine polymorphs by using Fourier-transformed reflection-absorption infrared spectroscopy and colorimetric measurement, J. Pharm. Pharmacol., 194, 162-167, Vol. 46	
	8	MATSUDA, Y. et al., Physicochemical characterization of furosemide modifications, international Journal of Pharmaceutics 1990, 11-26, Vol. 60	
	10	LIU, X et al., Inclusion of acitretin into cyclodextrins: phase solubility, photostability, and physicochemical characterization, Journal of Pharmaceutical Sciences, 2003, 2449-2457, Vol. 92, No. 12	
	11	HARRIS, K.D. et al., Probing polymorphism and reactivity in the organic solid state using 13c NMR spectroscopy: studies of p-formyl-trans-cinnamic acid, Journal of Solid State Chemistry, 1991, 197-205, Vol. 93	
	12	EL-SHAFEI, A. et al., Semi-empirical molecular orbital methods in the design of organic colorants, AATCC Review, 2001, 23-26, Vol. 1, NO. 12	
	13	GREENHILL, J.V., Is the photodecomposition of drugs predictable?, Photostability of Drugs and Drug Formulations, [International Meeting on Photostability of drugs], 1st, Oslo, June 1995 (1996), Meeting Date 1995, 83-110, Publisher: Taylor & Francis, London, UK	
	14	COHEN, M.D. et al., IIE. Influence of crystal structure on reactivity; Structure-Sensitive reactions of organic crystals, Proc. Intern. Symp. Reactivity Solids, 4th Amsterdam, 1961, 556-562,	
	15	NAKANISHI F. et al., Preparation of p-phenylenediacrylic acid salts and their photoreaction in the solid state, Kenkyu Hokoku-Sen'l Kobunshi Zairyo Kenkyusho, 1982, 39-43, Vol. 133	
·	16	ALBINI, A. et al., Photochemistry of Drugs, Handbook of Photochemistry and Photobiology, 2003, 147-193, American Scientific Publishers, Stevenson Ranch, California	

Application Number	10539505
Filing Date	2003-12-16
First Named Inventor	Rosenberg, et al.
Art Unit	1621
Examiner Name	Jennifer Y. Cho
Attorney Docket Number	065379-0053

		•	·	•				
	BOSCA, F. et al., A Laser flash photolysis study on fenofibric acid, Photochemistry and Photobiology, 1999, 853-857, Vol. 70, No. 6							
If you wis	If you wish to add additional non-patent literature document citation information please click the Add button							
			EXAMINER SIGNATURE					
Examine	Examiner Signature Date Considered							
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								
<sup>1</sup> See Kind Codes of USPTO Patent Documents at <a href="https://www.USPTO.GOV">www.USPTO.GOV</a> or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.								

( Not for submission under 37 CFR 1.99)

A	1000000		
Application Number	10539505		
Filing Date	2003-12-16		
First Named Inventor	Rosenberg. et al.		
Art Unit	1621		
Examiner Name	Jennifer Y. Cho		
Attorney Docket Number	065379-0053		

CERTIFICATION STATEMENT							
Plea	Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):						
	That each Item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).						
OR	OR						
	That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e)(2).						
X	⊠ See attached certification statement.						
SIGNATURE  A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.							
Sign	nature		Date (YYYY-MM-DD)	8/23/2007			
Name/Print		Lisa V. Mueller	Registration Number	1 38.978			
		•					

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.